Vimarsana
Biggest News Aggregation in the World

Rolling Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rolling Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rolling Review Today - Breaking & Trending Today

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) - Vimarsana News

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Published: February 9, 2024

BOSTON & LONDON, Feb. 09, 2024 -- Centessa Pharmaceuticals plc announced that data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of...

Source: marketscreener.com
Related Topics:
United StatesTrevor BaglinKristenk SheppardCentessa PharmaceuticalsDrug AdministrationAmerican Society Of HematologyExchange CommissionEuropean Association For HaemophiliaHemophilia At Centessa PharmaceuticalsAnnual CongressEuropean AssociationAllied DisordersAmerican SocietySaurabh SahaChief Executive OfficerGlobal HeadClinical TrialFast TrackAccelerated ApprovalPriority ReviewRolling ReviewAnnual ReportQuarterly ReportsInvestor Relations
South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain - Vimarsana News

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Published: November 1, 2023

/PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain...

Source: prnewswire.com
Related Topics:
United StatesHong KongJosh BlacherHernan BazanMental Health Services AdministrationNational Survey On DrugMental Health IndicatorsEuropean Patent OfficeRampart Pharma IncPharma IncSouth RampartKey MarketsGreater ChinaEuropean PatentUnified Patent Court ParticipatingEuropean UnitaryFast TrackAccelerated ApprovalPriority ReviewRolling ReviewNew Drug ApplicationSouth Rampart PharmaRampart PharmaTrack DesignationMortal Wkly
US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM - Vimarsana News

US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM

Published: August 11, 2023

PYC is a clinical-stage biotechnology company developing a pipeline of first-in-class precision medicines for patients who have genetic diseases and no...

Source: prnewswire.com
Related Topics:
Western AustraliaRohan HockingsTherapeutics LimitedDrug AdministrationRetinitis PigmentosaFast TrackAccelerated ApprovalPriority ReviewRolling ReviewNew DrugRetinitis Pigmentosa Type
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy - Vimarsana News

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy

Published: June 9, 2023

CRANBURY - Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need,... | June 9, 2023

Source: marketscreener.com
Related Topics:
Kevin GiordanoDrug AdministrationRocket Pharmaceuticals IncFast TrackOrphan DrugInvestigational New DrugRolling ReviewBiologic License ApplicationArrhythmogenic CardiomyopathyFanconi AnemiaLeukocyte Adhesion Deficiency IPyruvate Kinase DeficiencyDanon DiseasePrivate Securities Litigation Reform ActRisk FactorAnnual ReportQuarterly ReportsNews PublishingRocket PharmaceuticalsNc Stock ExchangePress ReleaseNmet Rckt Us77313f1066
Centessa Pharmaceuticals Receives Fast Track Designation - Vimarsana News

Centessa Pharmaceuticals Receives Fast Track Designation

Published: May 22, 2023

BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...

Source: globenewswire.com
Related Topics:
United StatesCity OfUnited KingdomKristenk SheppardExchange CommissionCentessa PharmaceuticalsDrug AdministrationFast TrackSaurabh SahaChief Executive OfficerAccelerated ApprovalPriority ReviewRolling ReviewAnnual ReportQuarterly ReportsNasdaq CntaCentessa Pharmaceuticals Plc